Table 1.
Patients’ Characteristics
| Characteristics | Number | % |
|---|---|---|
| Age (years) | ||
| Median (IQR) | 61 (18) | |
| ≦60 | 24 | 49.0 |
| > 60 | 25 | 51.0 |
| Gender | ||
| Male | 22 | 44.9 |
| Female | 27 | 55.1 |
| Performance status | ||
| 0 | 29 | 59.2 |
| 1 | 13 | 26.5 |
| 2 | 6 | 12.2 |
| 3 | 1 | 2.0 |
| Location of primary site | ||
| Extremities | 18 | 36.7 |
| Head and neck | 9 | 18.4 |
| Trunk | 16 | 32.7 |
| Unknown | 6 | 12.2 |
| Type | ||
| Acral melanoma | 15 | 30.6 |
| Non-acral cutaneous melanoma | 5 | 10.2 |
| Mucosal melanoma | 16 | 32.7 |
| Others | 7 | 14.3 |
| Unknown | 6 | 12.2 |
| Stage | ||
| 3 | 6 | 12.2 |
| 4, M1a | 5 | 10.2 |
| 4, M1b | 8 | 16.3 |
| 4, M1c | 30 | 61.2 |
| BRAF gene mutation | ||
| No | 34 | 69.4 |
| Yes | 9 | 18.4 |
| Unknown | 6 | 12.2 |
| Treatment regimen | ||
| Nivolumab | 33 | 67.3 |
| Pembrolizumab | 16 | 32.7 |
| Immunotherapy therapy | ||
| First-line | 31 | 63.3 |
| Second-or later-line | 18 | 36.7 |
| Response | ||
| CR | 2 | 4.1 |
| PR | 3 | 6.1 |
| SD | 9 | 18.4 |
| PD | 29 | 59.2 |
| N/A | 6 | 12.2 |
IQR interquartile range, CR complete response, PR partial response, SD stable disease, PD progressive disease, N/A not assessed